Comorbid patient with GERD and cardiovascular disease receiving antiplatelet therapy. The possibilities of choosing a proton pump inhibitor on a case study

Abstract

The high prevalence of cardiovascular disease and its frequent pathogenetic relationship with various comorbid diseases and conditions lead to polypragmasia and the development of undesirable adverse reactions. Treatment premorbidly disorders requires high clinical expertise and breadth of knowledge in the field of related disciplines that allows you to efficiently prescribe the appropriate drug therapy. It is important to emphasize that a patient with cardiovascular disease often receives antiplatelet therapy, including double, which can lead to adverse reactions from the upper gastrointestinal tract (due to the peculiarities of the mechanism of action of antiplatelet drugs), including from the esophagus, provoking the development or deterioration of gastroesophageal reflux disease (GERD). Proton pump inhibitors (PPI) are used for the prevention and treatment of these adverse events on the part of the gastrointestinal tract. Effective drug therapy for GERD also includes the administration of these drugs. However. Given the polymorbidity of patients and polypragmasia, the practitioner should strive to prescribe drugs with the lowest risk of drug interactions. These requirements are met by PPI rabeprazole, the metabolism of which is predictable. The use of this drug is presented in a clinical case.